My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

59.47 -0.05 (-0.08%)

Streaming Delayed Price Updated: 11:59 AM EST, Feb 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2

...

17 18 19 20 21 22 23 24 25

...

38 39 Next >

FDA AdComm Votes In Favor Of GSK's Jemperli Single Arm Trial Plan For Rectal Cancer Setting ↗

February 10, 2023

Via Benzinga

FDA Grants Complete Approval For GSK's Jemperli For Endometrial Cancer ↗

February 10, 2023

Via Benzinga

February 2023 Stock Considerations ↗

February 05, 2023

With a new trading month already in full swing, it is time to highlight some of my potential stock purchases. While the market had a nice bounce in recent months, there is still no shortage of stocks...

Via Talk Markets

Market Rally Powers Higher On Tame Fed, Meta Earnings; Apple, Google, Amazon In Focus: Weekly Review ↗

February 03, 2023

The major indexes continued to run despite mixed-to-weak earnings.

Via Investor's Business Daily

GSK CEO Emma Walmsley On Beating Q4 Earnings ↗

February 01, 2023

GSK came out with quarterly earnings of $0.64 per share.

Via Talk Markets

GSK Posts Higher Q4 Sales, Profits, With Record Sales From Shingles Vaccine ↗

February 01, 2023

Via Benzinga

Preview: GlaxoSmithKline's Earnings ↗

January 31, 2023

Via Benzinga

FDA Approves First Oral Treatment For Anemia Due To Chronic Kidney Disease ↗

February 02, 2023

Via Benzinga

Pharma Giants GSK, Novo Nordisk Beat Expectations; But Novartis Dives On A Mixed Report ↗

February 01, 2023

Two of the three companies easily beat sales and earnings expectations, but sales fell for the third.

Via Investor's Business Daily

February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More ↗

January 31, 2023

The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new...

Via Benzinga

CureVac Shares Pop After Encouraging Update From COVID-19, Flu mRNA Vaccine Programs ↗

January 30, 2023

Via Benzinga

Earnings Preview: GSK Q4 Earnings Expected To Decline ↗

January 25, 2023

This drug developer is expected to post quarterly earnings of $0.59 per share in its upcoming report, which represents a year-over-year change of -31.4%.

Via Talk Markets

GSK Earnings Conference Call Is Coming Up, Here's What You Need To Know ↗

January 23, 2023

Via Benzinga

Earnings Scheduled For February 1, 2023 ↗

February 01, 2023

Companies Reporting Before The Bell • Novo Nordisk (NYSE:NVO) is expected to report quarterly earnings at $0.85 per share on revenue of $6.84 billion.

Via Benzinga

The RSV Vaccine Battle Wages On With Moderna Scoring A Win Vs. Pfizer, GSK ↗

January 30, 2023

But Moderna stock didn't move higher on the announcement.

Via Investor's Business Daily

3 Penny Stocks That Could Make You Filthy Rich ↗

January 25, 2023

These low-priced equities could deliver enormous returns for risk-tolerant shareholders.

Via The Motley Fool

Sandoz Acquires Antifungal Agent From Astellas, Reinforcing Hospital Offering ↗

January 24, 2023

Via Benzinga

COVID, Shmovid: This Could Be the Next Big Growth Story for Moderna Stock ↗

January 21, 2023

Moderna could follow closely behind Pfizer and GSK in entering the lucrative RSV vaccine market.

Via The Motley Fool

Stock Market Rally Pulls Back; Microsoft, Google Slash Jobs; Netflix, Goldman, Tesla In Focus: Weekly Review ↗

January 20, 2023

Microsoft and Google are slashing jobs. Netflix and Tesla jumped.

Via Investor's Business Daily

Pharmaceutical Stocks Pfizer, GSK, Moderna Come Close To Cracking A Multibillion-Dollar RSV Vaccine Market ↗

January 19, 2023

After years of lab failures, the companies could crack open a multibillion-dollar market.

Via Investor's Business Daily

Jim Cramer Says This Stock Up 23% In A Month Is 'A Great Speculative Buy' ↗

January 18, 2023

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Biohaven Ltd (NYSE: BHVN) is a "great speculative buy."

Via Benzinga

Moderna Gets A 'Booster' Shot: Why Stock Is Up Nearly 7% Today ↗

January 18, 2023

Moderna, Inc. (NASDAQ: MRNA) shares were solidly higher in premarket trading on Wednesday.

Via Benzinga

Moderna Comes Swinging For Pfizer, GSK As RSV Vaccine Battle Heats Up ↗

January 17, 2023

Moderna is stepping up to Pfizer and GSK, both of which are developing RSV vaccines.

Via Investor's Business Daily

Week In Review: WuXi Biologics Out-Licenses Four TCE Antibodies To GSK In $1.5 Billion Pact ↗

January 07, 2023

WuXi Biologics out-licensed global rights for up to four pre-clinical bi- & multi-specific TCE antibodies to GSK in a $1.5 billion agreement. WuXi Biologics will receive $40 million upfront and up to...

Via Talk Markets

CureVac (CVAC) Stock Rises 25% on Positive Data for Covid-19 and Flu Vaccines ↗

January 06, 2023

CureVac announced positive results for its mRNA-based Covid-19 and flu vaccine, which may offer tremendous relevance for CVAC stock.

Via InvestorPlace

The Year of the Tripledemic

January 03, 2023

The Year of the Tripledemic

Via News Direct

Topics Death

What You Missed On Wall Street On Friday ↗

December 31, 2022

In the midst of markets falling, some companies had good news, while others took a hit from analysts and a merger is still on hold.

Via Talk Markets

GSK Looking For Under-Appreciated M&A Targets, Not Trying To Be Next Roche Or AstraZeneca ↗

December 30, 2022

GSK plc (NYSE: GSK) chief commercial officer Luke Miels says the company is looking at M&A targets that are under-appreciated worth $1 billion-$2.5 billion and avoid getting into a 'bidding war.'

Via Benzinga

7 Drug Stocks That Will Soar in 2023 ↗

December 22, 2022

These drug stocks to buy look poised to generate huge profits for investors in 2023 and in subsequent years.

Via InvestorPlace

2 Smartest Tech Stocks to Buy in 2022 and Beyond ↗

December 20, 2022

The tech space is still bursting with opportunities for long-term investors.

Via The Motley Fool

< Previous 1 2

...

17 18 19 20 21 22 23 24 25

...

38 39 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.